Pursuing the research and development of natural astaxanthin, we found that natural astaxanthin has an excellent pharmacological action to suppress chronic inflammation and is effective for preventing and treating various diseases including lifestyle diseases.
In modern society, various symptomatic treatment medicines have been prescribed in addition to diet therapy and exercise therapy for chronic diseases which are difficult to cure.
However, these medications might not achieving fundamental treatment.
We believe our new compounds we have discovered from the astaxanthin research have great potential and will become an innovative therapeutic agent which provides the new medical care for chronic inflammation which is said to be the origin of many diseases.
Our mission is to deliver new medicines to patients in the world by taking advantage of long experience and expert knowledge and skills in drug development.
We established Asta Pharmaceuticals Co., Ltd. to achieve this mission.
Along with aging society, the prevalence of chronic diseases and lifestyle diseases has increased, and the psychological, physical and economic burden of patients has been further increasing.
The cost of health and medical expenses and social infrastructure has become a burden on society more than ever.
We are convinced that our innovative medicine will bring solutions to patients and the society.
pursuit of innovation.
|Company name||Asta Pharmaceuticals Co., Ltd.|
|Established||October 15, 2015.|
|Representative||Mitsunori Nishida (President and chief executive officer)|
|Head Office||55, Yokohoonji Kamiichi-machi Nakaniikawa-gun, Toyama|
Takashi Fujita (Executive Vice President
Naoyuki Nishikawa (Executive Vice President)
Hiroshi Fujishita (Directors)
Dr. MaryJane Rafii (COO)
|Number of employees||16 individuals (as of April 1, 2019).|
|Group Company||Fuji Chemical Industries Co., Ltd. AstaReal Co., Ltd.|
|Business activities||Pharmaceutical Development|
President and chief executive officer
He was established Asta Pharmaceuticals Co., Ltd. and assumed the position of President and chief executive officer since 2015. He was appointed President and chief executive officer of Fuji Chemical Industry Co., Ltd. since 1995.
Joined Fuji Chemical Industry Co., Ltd. since 1978.
Previously he worked at Sankyo Co., Ltd. (1974-1977).
Executive Vice President
Takashi Fujita Ph.D.
Employed since 2015. Joined an advisor to Fuji Chemical Industry Co., Ltd. (2013-2014). He was established of HFX Pharma japan since 2008. Previously he worked at Daiichi Sankyo RD Associe., Ltd.(2007-2008), Chemtech Labo Inc.(2003-2007), and Sankyo Co., Ltd. (1973-2003).
Executive Vice President
Employed since January 2019. He was established of J1 Pharma Consulting since 2017. Previously he worked at Toray Co., Ltd. (2007-2016), and Sankyo Co., Ltd. (1975-2006).
Employed since June 2018.
Chief operating officer
MaryJane Rafii, Ph.D, MBA
Employed since 2017. Currently working as Adjunct Professor at UCONN Health Univ.
She worked at Wombat Capital (2016-2017), Sema Thera (2016-2017), Ora (2014-2016), Jade Therapeutics Inc. (2012-2016), Pfizer Inc. (2009-2012), Fovea pharma (2007-2009), Bioenvision Inc. (2005-2007), and The Ludwig Institute for Cancer Research (1999-2005).